MINNEAPOLIS--(BUSINESS WIRE)--Dec. 2, 2009--
Medtronic, Inc. (NYSE:MDT), today announced the appointment of Michael
J. Coyle as executive vice president and group president of its
Cardiology businesses. Coyle will lead all aspects of the group, which
includes the company’s Cardiac Rhythm Disease Management (CRDM),
CardioVascular and Physio-Control businesses. He will be a member of the
Executive Committee and report to Chairman and CEO Bill Hawkins.
Reporting to Coyle will be Pat Mackin, senior vice president and
president, CRDM; Scott Ward, senior vice president and president,
CardioVascular; and Brian Webster, president, Physio-Control.
“Mike brings to Medtronic more than 25 years of industry experience and
proven technical leadership, both complementing and strengthening the
exceptional management teams within our cardiac businesses,” said
Hawkins. “His deep experience in medical device therapy will enable us
to build on the emerging synergies within these businesses and to
accelerate their market leading performance.”
Prior to joining Medtronic, Coyle held a number of leadership positions
in the medical technology industry, most recently leveraging his broad
healthcare industry knowledge and expertise to advise and provide
leadership consulting services to private equity, venture capital and
medical device firms across the country. He served as president of St.
Jude Medical’s Cardiac Rhythm Management division from 2001 to 2007,
where he led that company’s global pacemaker, implantable cardioverter
defibrillator and cardiac resynchronization therapy businesses, and from
1997 to 2001, served as president of St. Jude’s Daig Catheter division.
Prior to St. Jude, he held various leadership positions at Eli Lilly &
Coyle received his master’s degree in business administration
specializing in finance and marketing from the Wharton School of
Business and also holds a chemical engineering degree from Case Western
Earlier this year, Medtronic announced it was consolidating its
businesses into two operating groups, which combined its Cardiac Rhythm
Disease Management CardioVascular and Physio-Control businesses; and the
other which combined its Spinal and Biologics, Neuromodulation,
Diabetes, and Surgical Technologies businesses. The move was designed to
leverage technologies, customers and synergies across its businesses and
to further advance its goal of One Medtronic - an integrated company
focused on the treatment of chronic disease.
Medtronic, Inc. (www.medtronic.com),
headquartered in Minneapolis, is the global leader in medical technology
– alleviating pain, restoring health, and extending life for millions of
people around the world.
Any forward-looking statements are subject to risks and uncertainties
such as those described in Medtronic’s Annual Report on Form 10-K for
the year ended April 24, 2009. Actual results may differ
materially from anticipated results.
Source: Medtronic, Inc.
Steve Cragle, 763-505-2345